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Abstract
Background: The pharmacokinetics of oral lysergic acid diethylamide are unknown despite its common recreational use and 
renewed interest in its use in psychiatric research and practice.
Methods: We characterized the pharmacokinetic profile, pharmacokinetic-pharmacodynamic relationship, and urine recovery 
of lysergic acid diethylamide and its main metabolite after administration of a single oral dose of lysergic acid diethylamide 
(200 μg) in 8 male and 8 female healthy subjects.
Results: Plasma lysergic acid diethylamide concentrations were quantifiable (>0.1 ng/mL) in all the subjects up to 12 hours after 
administration. Maximal concentrations of lysergic acid diethylamide (mean ± SD: 4.5 ± 1.4 ng/mL) were reached (median, range) 
1.5 (0.5–4) hours after administration. Concentrations then decreased following first-order kinetics with a half-life of 3.6 ± 0.9 
hours up to 12 hours and slower elimination thereafter with a terminal half-life of 8.9 ± 5.9 hours. One percent of the orally 
administered lysergic acid diethylamide was eliminated in urine as lysergic acid diethylamide, and 13% was eliminated as 
2-oxo-3-hydroxy-lysergic acid diethylamide within 24 hours. No sex differences were observed in the pharmacokinetic profiles 
of lysergic acid diethylamide. The acute subjective and sympathomimetic responses to lysergic acid diethylamide lasted up to 
12 hours and were closely associated with the concentrations in plasma over time and exhibited no acute tolerance.
Conclusions: These first data on the pharmacokinetics and concentration-effect relationship of oral lysergic acid diethylamide 
are relevant for further clinical studies and serve as a reference for the assessment of intoxication with lysergic acid diethylamide.
Keywords: LSD, O-H-LSD, pharmacokinetics, pharmacodynamics, plasma, urine
Trial registration: Registration identification number: NCT01878942
ClinicalTrials.gov: http://clinicaltrials.gov/ct2/show/NCT01878942.
Introduction
Lysergic acid diethylamide (LSD) is a prototypical hallucinogen 
(Nichols, 2004; Passie et al., 2008). LSD became famous as a psyche-
delic in the 1960s, and its recreational use continues (Passie et al., 
2008). However, no clinical research has been conducted with LSD 
since the 1970s until recently (Gasser et al., 2014; Kupferschmidt, 
2014). Almost no scientific clinical pharmacological data on LSD 
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are available. Specifically, the pharmacokinetics (PK) of oral LSD 
in humans are unknown. A small PK study administered single 
intravenous doses of 2 μg/kg in 5 healthy male human subjects 
(Aghajanian and Bing, 1964). Blood samples were taken up to 8 
hours after administration. Plasma concentrations were 6 to 
7 ng/mL 30 minutes after intravenous administration, 4–6 ng/mL 
at 30–120 min, and approximately 1 ng/mL at 8 hours. The mean 
plasma elimination half-life of LSD was estimated at 175 minutes 
in this previous study. In another study, single oral doses of 160 μg 
were administered to 13 male human subjects, and blood was 
sampled nonsystematically at various time points up to a maxi-
mum of 2.5 to 5 hours. Plasma levels peaked 40 to 130 minutes 
after LSD administration, and peaks ranged from 1.8 to 8.8 ng/mL 
(Upshall and Wailling, 1972). The dataset and short sampling time 
did not allow the calculation of PK parameters.
The aim of the present study was to characterize the single-
dose kinetics and PK-pharmacodynamic relationships of LSD 
in healthy male and female subjects. For clinical and forensic 
toxicologists, it is important to know the toxicokinetics of LSD 
and how plasma concentrations of LSD are linked to its dynamic 
effects and signs of intoxication.
LSD was administered in a single oral dose of 200 μg. The 
same dose was used in a clinical study (Gasser et al., 2014). The 
dose used was within the range of doses (50–400 μg) taken for 
recreational purposes and expected to induce a full “LSD reac-
tion” (Nichols, 2004; Passie et  al., 2008). The study also evalu-
ated the acute subjective, autonomic, and endocrine effects of 
LSD. The pharmacodynamics are reported in detail elsewhere 
(Schmid et  al., 2014), but the PK-pharmacodynamic relation-
ships are presented herein.
Methods
Study Design
The study used a double-blind, placebo-controlled, cross-over 
design with 2 experimental test sessions in balanced order. The 
washout periods between sessions were at least 7 days. The study 
was conducted in accordance with the Declaration of Helsinki 
and International Conference on Harmonization Guidelines in 
Good Clinical Practice and approved by the Ethics Committee 
of the Canton of Basel, Switzerland and the Swiss Agency for 
Therapeutic Products (Swissmedic). The administration of LSD 
to healthy subjects was authorized by the Swiss Federal Office 
for Public Health, Bern, Switzerland. The study was registered 
at ClinicalTrials.gov (NCT01878942). All of the subjects pro-
vided written informed consent after being given written and 
oral descriptions of the study, the procedures involved, and the 
effects and possible risks of LSD administration.
Participants
Sixteen healthy subjects (8 men and 8 women; mean age ± SD: 
28.6 ± 6.2 years; range: 25–51 years) were included. The exclusion 
criteria are reported in detail elsewhere (Schmid et al., 2014) and 
included age <25 or >65  years, pregnancy, personal or family 
(first-degree relative) history of psychotic or major affective dis-
order, regular use of medications, chronic or acute physical ill-
ness, lifetime prevalence of illicit drug use >10 times (except for 
tetrahydrocannabinol), illicit drug use within the last 2 months, 
and illicit drug use during the study. Nine subjects were halluci-
nogen-naive, and the other 7 had limited prior experience with 
hallucinogenic drugs, including 1 subject who had used LSD 
once and 2 subjects who had used LSD twice. The subjects were 
asked to abstain from excessive alcohol consumption between 
test sessions and particularly limit their use to 1 drink on the 
day before the test sessions. Additionally, the participants were 
not allowed to drink xanthine-containing liquids after mid-
night before the study day. Three subjects were light smokers 
(<10 cigarettes/d) and were told to maintain their usual smok-
ing habits but not smoke during the sessions. We performed 
urine drug tests at screening and before each test session using 
TRIAGE 8 (Biosite, San Diego, CA). No alcohol test was performed.
Study Outline
The test sessions began at 8:15 AM. A urine sample was taken to 
verify abstinence from drugs of abuse, and a pregnancy test was 
performed in women. An indwelling intravenous catheter was 
placed in an antecubital vein for blood sampling, and the sub-
jects completed baseline measurements. LSD (200 µg) or placebo 
was administered at 9:00 AM. A standardized lunch and dinner 
was served at 1:30 PM and 5:30 PM, respectively. The subjects 
were sent home the next day at 9:30 AM after the 24-hour blood 
sample collection
Drugs
Gelatin capsules that contained 100  µg LSD (D-LSD hydrate 
with a purity (high-performance liquid chromatography) >99%; 
Lipomed AG, Arlesheim, Switzerland), and corresponding pla-
cebo capsules were prepared with authorization from the Swiss 
Federal Office for Public Health. LSD was administered in a single 
absolute dose of 200 µg, corresponding to a dose of 2.84 ± 0.5 µg/
kg body weight (mean ± SD; range: 2.04–3.85 μg).
Blood and Urine Sampling
Blood was collected into lithium heparin tubes 1 hour before and 
0.5, 1, 1.5, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 hours after LSD admin-
istration. Urine (entire volume) was collected during 3 sampling 
periods: 0 to 8, 8 to 16, and 16 to 24 hours after LSD administra-
tion. Blood samples were immediately centrifuged, and plasma 
and urine were rapidly stored at -20°C until analysis within 2 
to 6  months. Long-term stability (6  months) has been shown 
for LSD and 2-oxo-3-hydroxy-LSD (O-H-LSD) when kept under 
refrigerated or frozen conditions (Klette et al., 2002; Martin et al., 
2013). The recovery (ng) of LSD and O-H-LSD was determined by 
multiplying the analyte urine concentrations (ng/mL) with the 
urinary volume (mL) of the respective sampling interval.
Analysis of LSD and O-H-LSD
LSD and O-H-LSD concentrations in plasma and urine were 
determined using a validated liquid-chromatography-tandem 
mass-spectrometry method as reported in detail in the supple-
mentary Material online and elsewhere (Dolder et al., 2015). The 
lower limit of quantification was 0.1 ng/mL, and the upper limit 
of quantification was 10 ng/mL for LSD and O-H-LSD in both 
plasma and urine.
PK
The plasma concentration data were analyzed using noncom-
partmental methods using Phoenix WinNonlin 6.4 (Certara, 
Princeton, NJ). Cmax and Tmax values were obtained directly from 
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the observed data. The area under the concentration-time 
curve (AUC) from 0 to 24 hours after dosing (AUC24) was cal-
culated using the linear-up log-down trapezoidal method. The 
terminal elimination rate constant (λz) for LSD was estimated 
by log-linear regression after semilogarithmic transformation 
of the data using at least the last 3 data points of the termi-
nal linear phase of the concentration-time curve. The terminal 
half-life was calculated using λz and the equation t1/2 = ln2/λz. 
The AUC to infinity was then determined by extrapolation of 
the AUC24 using λz. We also determined a separate half-life for 
the Tmax to 12 hour interval, because the rate of elimination 
changed at 12 hours in many subjects (see supplementary 
Figure S1 for all plots), and the decrease in plasma concentra-
tions followed first-order kinetics in all subjects from Tmax to 
12 hours. For this phase, we estimated the elimination rate 
constant (λ) for LSD using at least 3 data points of the con-
centration-time curve. Thus, this half-life does not describe 
the slower decrease in the concentration of LSD observed in a 
subset of subjects beyond 12 hours or 16 hours. Individual con-
centration-time curves show that a slower terminal decrease 
in LSD concentrations occurred only beyond 12 hours (after 
eating dinner and during the night) and not concentration-
dependent (ie, was not observed below a certain threshold 
concentration of LSD; see supplementary Figure S1). Renal 
clearance (mL/h) was calculated as urinary recovery24 urine (ng)/
AUC24 (ng∙h/mL).
Statistical Analyses
The analysis of the pharmacokinetic parameters was descrip-
tive, and geometric means and 90% CIs are shown to account for 
nonnormally distributed data. The study included 8 subjects of 
each sex; the data are also presented for male and female sub-
jects separately. However, the study was not sufficiently pow-
ered (power: 52%) to exclude sex differences in the PK of LSD 
(PASS Power Analysis, Kaysville, UT).
The primary pharmacodynamic study results were reported 
elsewhere (Schmid et  al., 2014). The a priori hypothesis relat-
ing to the PK-pharmacodynamics as defined in the study pro-
tocol was that the pharmacodynamic effects of LSD would 
show no acute pharmacological tolerance (ie, no clockwise 
hysteresis in the concentration-effect relationship). To assess 
PK-pharmacodynamic relationships, the LSD-induced effect was 
determined as a difference from placebo in the same subject at 
the corresponding time point to control for circadian changes 
(Schmid et al., 2014). The pharmacodynamic changes after LSD 
administration for each time point were plotted against the 
respective plasma concentrations of LSD and graphed as hyster-
esis curves for each subject. Because pupil size measurements 
were unavailable at the same time points as plasma levels, pupil 
size values at 7 and 11 hours were matched with concentrations 
at 8 and 12 hours. No pupil size measurement was available for 
the 24-hour time point; therefore, we used the baseline value 
at t = 0 hours, assuming a return to baseline by 24 hours. The 
area within the hysteresis (AH) was calculated as AUCC0-Cmax – 
AUCCmax-C24 using the trapezoidal rule. AH < 0 indicates counter-
clockwise hysteresis (lag time between concentration and effect 
due to absorption/distribution processes). AH > 0 indicates clock-
wise hysteresis (tolerance).
To estimate the plasma concentration of LSD at which 50% 
of the maximal response to LSD is reached (EC50), a sigmoi-
dal concentration-response (variable slope) model was fitted 
to the plasma concentration-effect data: E = (Emax × Cp
h) / (Cp
h + 
EC50
h), in which E is the observed effect, Cp is the plasma LSD 
concentration, Emax is the maximal effect, and h is the Hill slope 
using WinNonlin. Because of the hysteresis observed for most 
plasma-concentration effect curves, an indirect descriptive link 
model would be needed in which the plasma concentrations are 
linked to the pharmacodynamic parameter by an effect com-
partment, providing an estimate of the equilibration half-life 
between plasma and the effect compartment. However, because 
insufficient data pairs for the absorption phase (0-Cmax) were 
available, we directly linked dynamic effects to the plasma con-
centrations using only data from Cmax up to 24 hours after drug 
administration for this analysis. Statistical analyses were con-
ducted using NCSS 2004 software (Statistical Software, Kaysville, 
UT).
Pharmacodynamic Measurements
Pharmacodynamic measures were included in this study to 
evaluate PK-pharmacodynamic relationships. Subjective effects 
were assessed repeatedly over time using visual analog scales 
(VASs) (Hysek et  al., 2014), including “any drug effect,” “good 
drug effect,” and “bad drug effect.” The VASs were presented as 
100-mm horizontal lines marked with “not at all” on the left and 
“extremely” on the right. The VASs were administered 0, 0.5, 1, 
1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, and 24 hours after drug 
administration. Vital signs, including blood pressure, heart rate, 
and body (tympanic) temperature, were assessed repeatedly 0, 
0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours after drug adminis-
tration using previously reported methods (Hysek et al., 2014). 
Additionally, pupil size (dark-adapted maximal pupil diameter) 
was measured 1, 2.5, 4, 7, and 11 hours after drug administration 
using an infrared pupillometer (PRL-200, NeurOptics, Irvine, CA) 
under standardized dark-light conditions as previously reported 
(Hysek and Liechti, 2012).
Results
PK
Figure 1 shows the plasma-concentration-time curves for LSD 
and O-H-LSD. The PK parameters are shown in Table  1. The 
plasma concentrations of LSD (>0.1 ng/mL) could be measured 
in all of the subjects up to 12 hours, in 14 subjects up to 16 
hours, and in 11 subjects up to 24 hours after administration. 
Concentrations of LSD decreased following first-order kinet-
ics up to 12 hours with a half-life of 3.6 ± 0.9 hours (Figure 1b). 
In some subjects, a slower decrease in plasma concentrations 
was observed late in time between 12 and 24 hours. This slower 
decrease occurred after the subjective effects of LSD had mostly 
subsided and the individual concentration-time curves showed 
that the slower decrease was dependent on time >12 hours (after 
eating dinner and during the night) and not on concentration 
(ie, below a certain concentration of LSD) (see supplementary 
Figure S1). The terminal half-life was 8.9 ± 5.9 hours including 4 
subjects (S4-S7, see supplementary Figure S1) in whom concen-
trations of LSD at 24 hours showed no further decrease com-
pared with the 16-hour concentrations.
The O-H-LSD concentration-time profiles could be deter-
mined for only 8 subjects, because metabolite concentrations 
were not present or fell below the lower limit of quantification in 
one-half of the subjects (Figure 1c-d). We could not show a differ-
ence in the pharmacokinetic profiles of LSD between male and 
female subjects (Table 1). The concentrations of LSD and O-H-LSD 
in urine and the urine recovery of LSD and O-H-LSD are shown in 
Table 2. The mean molar concentrations of O-H-LSD (molecular 
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Table 2. Urinary Elimination of LSD and O-H-LSD
N=
LSD O-H-LSD
0–8 hours 8–16 hours 16–24 hours 0–24 hours 0–8 hours 8–16 hours 16–24 hours 0–24 hours
Urinary concentrations (ng/mL)
 all 16 0.96 ± 0.8 1.1 ± 1.8 0.70 ± 0.6 8.3 ± 4.7 17.7 ± 11 14.4 ± 10
 male 8 0.78 ± 0.4 0.82 ± 0.2 0.66 ± 0.6 6.6 ± 3.4 22.7 ± 14 11.2 ± 7
 female 8 1.1 ± 1.0 1.5 ± 2.6 0.74 ± 0.7 9.9 ± 5.4 12.7 ± 5.3 17.6 ± 12
Urinary volume (L)
 all 16 1.4 ± 0.7 0.79 ± 0.4 0.47 ± 0.3
 male 8 1.8 ± 0.8 0.86 ± 0.5 0.63 ± 0.2
 female 8 1.1 ± 0.5 0.71 ± 0.4 0.30 ± 0.2
Urinary recovery (nM) Ae0-24
 all 16 3.6 ± 2.6 2.0 ± 1.7 0.82 ± 0.5 6.4 ± 2.9 28.3 ± 15 35.9 ± 27 15.3 ± 7.8 79.5 ± 41
 male 8 3.8 ± 2.4 2.0 ± 0.8 1.1 ± 0.6 6.8 ± 2.6 29.3 ± 19 49.6 ± 33 17.1 ± 8.6 96.1 ± 51
 female 8 3.5 ± 2.8 2.0 ± 2.3 0.58 ± 0.3 6.0 ± 3.3 27.3 ± 13 22.3 ± 9* 13.4 ± 6.8 62.9 ± 18
Abbreviations: Ae, amount eliminated in nM; LSD, lysergic acid diethylamide; O-H-LSD, 2-oxo-3-hydroxy-LSD.
*Significant difference from men (P < .05). Values are mean ± SD.
Figure 1. Pharmacokinetics (PK) of lysergic acid diethylamide (LSD) and 2-oxo-3-hydroxy-LSD (O-H-LSD). (a) Individual LSD plasma concentration-time curves with the 
geometric mean shown in the inset. Filled circles indicate male subjects, and open circles indicate female subjects. (b) Semilogarithmic plot of the individual concen-
trations of LSD. Curves are shown separately for each individual in the supplementary Material (supplementary Figure S1). First-order kinetics were observed in all 16 
subjects up to 12 hours. LSD levels fell below the lower limit of quantification (0.1 ng/mL) in 2 subjects at 16 hours and 5 subjects at 24 hours. Slower elimination was 
observed between 12 and 24 hours. (c) Individual O-H-LSD plasma concentration-time curves in 8 subjects in whom metabolite concentrations could be determined, 
with the geometric mean shown in the inset. (d) Semilogarithmic plot of the individual concentrations of O-H-LSD. Curves are shown separately in supplementary 
Figure S2. LSD was administered at t = 0 hours.
Table 1. Pharmacokinetic Parameters for LSD and O-H-LSD
N=
Cmax (ng/ml) 
Geometric  
Mean (95%CI)
tmax (h) Median 
(range)
t1/2 (h) 
Tmax-12 h 
Mean ± SD
t1/2 (h) Terminal 
Mean ± SD
AUC24 (ng·h/ 
mL) Geometric 
Mean (90%CI)
AUC∞ (ng·h/ 
mL) Geometric 
Mean (90%CI)
CLR (mL/min) 
Mean ± SD
LSD All 16 4.3 (3.8–4.9) 1.5 (0.5–4) 3.6 ± 0.9 8.9 ± 5.9 26 (22–30) 28 (24–33) 79 ± 36
LSD Male 8 4.4 (3.6–5.3) 1.5 (0.5–4) 3.5 ± 1.0 10.2 ± 6.7 25 (18–35) 28 (20–38) 88 ± 36
LSD Female 8 4.2 (3.4–5.3) 1.5 (0.5–3) 3.8 ± 0.8 7.6 ± 5.1 26 (23–30) 28 (25–32) 71 ± 36
aO-H-LSD All 8 0.4 (0.3–0.5) 4 (2.5–6) 3.4 (2.6–4.3) 3.8 (2.8–5.3)
Abbreviations: AUC, area under the plasma concentration-time curv; AUC∞, AUC from time zero to infinity; AUC24, from time 0–24; CLR, renal clearance; Cmax, maxi-
mum observed plasma concentration; T1/2, plasma half-life; Tmax, time to reach Cmax; 
aO-H-LSD levels were above the limit of detection in only 8 subjects).
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weight: 355.4) were 23.2, 49.9, and 40.6 pM/mL and 8, 14, and 19 
times higher than the mean molar concentrations of LSD (molec-
ular weight: 323.4; 3.0, 3.5, 2.2 pM/mL) in the 0 to 8, 8 to 16, and 
16 to 24 hour sampling intervals, respectively. Of the nonmetabo-
lized LSD that was recovered from urine, 56% appeared in urine 
within the first 8 hours after administration and 45% of the O-H-
LSD appeared in urine 8 to 16 hours after LSD administration. 
Of the orally administered LSD hydrate (200 μg or 618 nM), 13% 
was eliminated in urine as O-H-LSD (28.3 μg or 79.5 nM) within 
24 hours. Only 1% (2.1 μg or 6.4 nM) of the dose of LSD was elim-
inated in urine as LSD within 24 hours. The renal clearance of 
LSD was 1.32 ± 0.6 mL/min or approximately 1.6% of the apparent 
total clearance after oral administration (CL/F), assuming an oral 
bioavailability of 71% (see Discussion). No significant differences 
in LSD or O-H-LSD urine concentrations were observed between 
male and female subjects (Table 2). The urine recovery of O-H-LSD 
was greater in male subjects than in female subjects during the 
8 to 16 hour sampling period, but no significant differences were 
observed in the overall 0 to 24 hour sampling (Table 2).
PK-Pharmacodynamic Relationship
Figure 2 shows the effects of LSD as a function of plasma con-
centration. There was a close relationship between the LSD con-
centration and its dynamic effects overt time. No hysteresis was 
found for heart rate (Figure 2a), blood pressure (Figure 2b), or bad 
drug effect (Figure 2g). The 95% CIs of the mean of the area within 
the hysteresis loops (AH) overlapped with 0 for heart rate (4.4 
beats × ng/min × mL [-13 to +22]), blood pressure (-5 mgHg × ng/
min × mL [-24 to +13]), and bad drug effect (5% × ng/min × mL 
[-29 to +38]), indicating no hysteresis. Counterclockwise hyster-
esis (negative AH value) was observed, attributable to relatively 
higher plasma levels compared with the dynamic effects dur-
ing the assumed drug absorption phase (0–2 hours) for body 
temperature (Figure  2c), pupil size (Figure  2d), any drug effect 
(Figure 2e), and good drug effect (Figure 2f). Mean AH values (95% 
CI) were the following: body temperature (-1°C × ng/min × mL 
[-1.5 to -0.5]), pupil size (-1.4  mm × ng/min × mL [-2.2 to -0.7]), 
any drug effect (-78% × ng/min × mL [-113 to -43]), and good drug 
effect (-106% × ng/min × mL [-151 to -61]). The decline of the 
response to LSD and plasma concentration over time followed a 
sigmoidal Emax dose-response curve for any drug effect and good 
drug effect. The EC50 mean ± SD values were 1.3 ± 0.7 ng/mL for 
any drug effect and 1.0 ± 0.5 ng/mL for good drug effect. Heart 
rate, blood pressure, body temperature, and bad drug effect 
linearly increased with plasma concentrations of LSD and did 
not show an Emax (Figure 2a-c, g). Not enough values were avail-
able to fit changes in pupil size. No clockwise hysteresis was 
observed for any of the concentration-effect curves, meaning 
that the dynamic values were higher later in time at a given 
Figure 2. Lysergic acid diethylamide (LSD) effects plotted against LSD plasma concentrations (geometric means). The pharmacodynamic values are the mean ± SEM 
differences from placebo at each time point in 16 subjects. The time of sampling is noted next to each point (in hours after LSD administration). Heart rate (a), mean 
arterial pressure (b), and bad drug effect (g) showed no hysteresis. Counterclockwise hysteresis was observed for body temperature (c), pupil size (d), any drug effect (e), 
and good drug effect (f), consistent with a delay between plasma concentration and effect. For most dynamic variables, maximal plasma concentrations (at approxi-
mately 2 hours) coincided with maximal dynamic effects. The dynamic changes then gradually decreased over time with decreasing plasma levels. No evidence of 
acute tolerance (clockwise hysteresis) was observed for any of the dynamic effects of LSD.
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plasma concentration and consistent with no acute tolerance to 
the effects of LSD. LSD produced acute adverse effects, including 
difficulty concentrating, headache, exhaustion, and dizziness 
lasting up to 24 hours and as reported elsewhere (Schmid et al., 
2014). There were no severe adverse effects.
Discussion
The present study determined the single-dose PK of oral LSD in 
humans. The concentrations of LSD were maximal after 1.5 hours 
(median) and gradually declined to very low levels by 12 hours. We 
observed first-order kinetics of LSD up to 12 hours in all subjects 
and an inconsistent slower decrease in concentrations thereafter 
in some subjects. This could be attributable to redistribution from 
tissue or due to less precise quantification of the very low plasma 
levels of LSD at 12 to 24 hours (ie, close to the lower limit of quan-
tification). The half-life of 3.6 hours during the first 12 hours after 
drug administration is close to the 3 hours previously observed 
in a small study that used intravenous LSD administration 
(Aghajanian and Bing, 1964). Only 1% of the orally administered 
LSD was eliminated renally. LSD is almost completely metabo-
lized in rats, guinea pigs, and monkeys (Axelrod et al., 1957; Siddik 
et al., 1979). In humans, the major metabolite of LSD detectable in 
urine is O-H-LSD (Klette et al., 2000; Poch et al., 2000; Canezin et al., 
2001). In the present study, O-H-LSD was detected in blood plasma 
at very low concentrations and in only one-half of the subjects. 
The urine concentrations of O-H-LSD in the present study were 
approximately 10, 15, and 20 times higher than those of LSD at 0 
to 8, 8 to 16, and 16 to 24 hours after LSD administration. Similarly, 
in LSD-positive forensic urine samples, O-H-LSD concentrations 
are higher than those of LSD, and O-H-LSD can be detected for 
a longer time than LSD after LSD administration (Reuschel et al., 
1999; Klette et  al., 2000; Poch et  al., 2000). In the present study, 
13% of the orally administered LSD was recovered from urine 
as O-H-LSD within 24 hours. LSD is metabolized to O-H-LSD by 
cytochrome P450 enzymes, but the specific enzymes and mech-
anisms are unknown (Klette et al., 2000). To our knowledge, it is 
unknown whether O-H-LSD is pharmacologically active.
The oral bioavailability of LSD can be crudely estimated 
using the previous data on intravenous LSD administration 
(Aghajanian and Bing, 1964) and our data on oral LSD. After intra-
venous LSD administration (2 μg/kg of the free base in 5 male 
subjects), a mean total plasma exposure (AUC∞) of 31.4 ng∙mL/h 
was obtained (15.7 ng∙mL/h per μg/kg free base), calculated based 
on the published plasma concentration profile (Aghajanian and 
Bing, 1964). After oral LSD administration in the present study 
(2.5  μg/kg free base in 8 male subjects), the mean AUC∞ was 
28 ng∙mL/h (11.2 ng∙mL/h per μg/kg free base). Based on these 
data, the oral bioavailability of LSD is approximately 71%. In the 
present study, LSD was administered after a light meal. When 
ingested with a “full breakfast,” oral LSD was reported to result 
in lower plasma concentrations compared with administration 
on an empty stomach (Upshall and Wailling, 1972). However, 
these observations were made in only 2 to 3 subjects (Upshall 
and Wailling, 1972) and would need confirmation. Remaining to 
be tested is whether food reduces or delays the absorption of oral 
LSD. Additionally, the PK profiles were similar in male and female 
subjects. However, the study was too underpowered to statisti-
cally exclude sex differences in the PK of LSD.
We found a close relationship between the plasma con-
centrations of LSD and physiologic response or psychotropic 
effects of LSD over time. Estimated EC50 values for the psycho-
tropic effects were in the range of 1.0 to 1.3 ng/mL (approxi-
mately 3–4 nM). The unbound fraction of LSD in human plasma 
is unknown. In cats, the unbound fraction was 0.2, and LSD 
concentrations in cerebrospinal fluid were similar to free LSD 
plasma concentrations (Axelrod et al., 1957). Thus, LSD concen-
trations of 0.6 to 0.8 nM could be expected in cerebrospinal fluid. 
These values are in the range of the binding affinity of LSD at 
the 5-hydroxytryptamine-2A (5-HT2A) receptor (Ki  = 0.4–1.3 nM, 
respectively) (Titeler et al., 1988; Egan et al., 1998) and also close 
to the EC50 for the functional stimulant activity of LSD at the 
receptor in vitro (EC50 = 7.2 nM) (Egan et al., 1998). Pupil size was 
also strongly increased at low concentrations of LSD. We pre-
viously showed that pupil diameters were significantly larger 
compared with placebo until the last pupil measurement at 11 
hours after LSD administration. In contrast, elevations in blood 
pressure, heart rate, and body temperature were only significant 
up to 5 hours after LSD administration compared with placebo, 
as reported elsewhere (Schmid et  al., 2014). Additionally, the 
increases in heart rate, blood pressure, body temperature, and 
bad drug effects showed no ceiling effect in the concentration-
effect curves, in contrast to the other dynamic effects of LSD. 
Heart rate, body temperature, blood pressure, and bad drug 
effects would likely increase further with higher doses of LSD, 
whereas the pupillary or good subjective effects can be expected 
to be similar to those seen in the present study. The hyperten-
sive effects of LSD may result from 5-HT2A and/or α1-adrenergic 
receptor-mediated vasoconstrictive effects at higher doses (Dyer 
and Gant, 1973; Blessing and Seaman, 2003).
No evidence of acute tolerance was observed, which would 
become apparent as clockwise hysteresis in the concentration-
response curve and has been shown for 3,4-methylenediox-
ymethamphetamine (MDMA) (Hysek et  al., 2011). In contrast 
and as typically expected for most drugs, counterclockwise 
hysteresis was observed early in time until the end of the 
assumed drug absorption phase. No similar studies on the 
PK-pharmacodynamic relationship of LSD have been performed. 
Only one other small study measured plasma LSD concentra-
tions and concomitant pharmacodynamic effects (Aghajanian 
and Bing, 1964). LSD was administered intravenously in 5 male 
subjects. To obtain a crude index of performance, subjects 
were given one of a series of equivalent tests, consisting of 
simple addition problems, after each blood sample was drawn 
(Aghajanian and Bing, 1964). After the distribution phase (30 
minutes after intravenous LSD administration), the impair-
ments in performance declined in parallel with the plasma 
levels of LSD, also suggesting a close temporal relationship 
between the PK and pharmacodynamics of LSD (Aghajanian 
and Bing, 1964). In contrast to the single-dose administration in 
the present study, tolerance to the subjective effects of LSD with 
repeated daily LSD administration has been reported (Abramson 
et al., 1956; Belleville et al., 1956). However, a gradual increase 
in head twitches and catatonic postures and no tolerance was 
observed up to 3 to 4  days after continuous LSD administra-
tion in rats (Ellison et al., 1980). Also in contrast to our findings 
with LSD, we observed pronounced acute tolerance to the psy-
chotropic and cardiostimulant effects of MDMA using the same 
methodology (Hysek et al., 2011). As a result, the pharmacody-
namic effects of MDMA last significantly shorter than would 
be expected based on plasma levels. The subjective and cardi-
ostimulant effects of MDMA last only 5 hours despite its long 
half-life of 10 hours (Hysek et al., 2011). In contrast, the subjec-
tive drug effects of LSD lasted for 12 hours in most subjects and 
up to 16 hours in some subjects in the present study despite 
LSD’s shorter half-life. Thus, subjects with MDMA in blood may 
no longer be clinically intoxicated, whereas subjects with quan-
tifiable LSD concentrations in plasma are clinically intoxicated. 
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A mechanistic explanation for this acute tolerance in the case 
of MDMA is that it mainly produces its acute effects through 
the release of endogenous serotonin and norepinephrine (ie, 
as an indirect serotonergic and noradrenergic agonist). In con-
trast, LSD is thought to produce its psychotropic hallucinogenic 
effects through a direct interaction with the 5-HT2A receptor (ie, 
as a direct serotonergic agonist), resulting in pharmacodynamic 
effects to which no acute tolerance was observed in our study.
In summary, we show first data on the PK and 
PK-pharmacodynamic relationship of oral LSD in human sub-
jects. The PK profiles exhibit first-order kinetics of LSD up to 
12 hours. LSD produces physiological and psychotropic effects 
lasting up to 12 hours, closely related to the plasma concentra-
tions of LSD and inhibiting no acute tolerance. The findings are 
important for further clinical studies and serve as a reference 
for the assessment of intoxication with LSD.
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